Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB4211
    • CB5138 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay
News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Dec 16, 2019 9:00am EST

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

Nov 06, 2019 4:04pm EST

CohBar Reports Third Quarter 2019 Financial Results and Business Update

Nov 05, 2019 9:00am EST

CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

Oct 24, 2019 9:00am EDT

CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019

Oct 23, 2019 8:45am EDT

CohBar Expands Board with Biotech Veteran Misha Petkevich

Oct 15, 2019 9:00am EDT

CohBar to Present at the 2019 BIO Investor Forum

Sep 18, 2019 9:00am EDT

CohBar to Present at the 2019 Cantor Global Healthcare Conference

Aug 07, 2019 4:05pm EDT

CohBar Reports Second Quarter 2019 Financial Results and Business Update

Jul 31, 2019 4:05pm EDT

CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

Jun 10, 2019 9:00am EDT

CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 19
  • Next Pagearrow_forward
©2023 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use